Community/Retail

Kala Shankle, JD, and Lisa Schwartz, PharmD, RPh, discuss the DSCSA and what it means for pharmacists. This video was filmed at the 2019 NCPA Annual Convention in San Diego.

Utilizing many of the skills learned in pharmacy school could help to personalize care and enhance medication delivery for patients, potentially leading to reductions in adverse drug events and health care costs,

Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.

Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.